Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.

Inclusion Criteria: * Healthy participants; * Non-injured skin in the test region; * Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations; * Ability to consent to participation in the study; * Phototype (Fitzpatrick): II and III; Exclusion Criteria: * Pregnant or breastfeeding women; * Use of the following systemic drugs: antihistamines, non-hormonal anti-inflammatory drugs and corticoids; * History of allergy to cosmetics, topical products or research product; * Localized or widespread dermatological diseases or inflammatory dermatoses active and nerve damage in the test region; * Personal or family pathological history of skin cancer; * Use of topical or systemic photosensitizing medication; * History of phototoxic, photoallergic reactions, dermatoses caused by light, atopy, pathologies aggravated or triggered by ultraviolet radiation; * Photo-induced pathologies; * Frequent exposure to the sun or tanning chambers; * Participated in an allergenicity study in a period of less than 4 weeks from the start of the study; * Skin marks in the experimental area that interfere with the evaluation of possible reactions; * Active dermatoses; * Forecast to take a bath in the sea, pool or sauna during the study; * Participants who play water sports; * Dermography; * Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection or, considering deposit corticoids, the interval shall be 1 month prior to selection; * Treatment with acid vitamin A and/or its derivatives via oral or topical until 1 month before the beginning of the study; * Aesthetic and/or body dermatological treatment until 3 weeks before selection; * Vaccination during the study or until 3 weeks before the study; * Being participated in another clinical trial.